Key result
RAS inhibitors and ibuprofen show no link to increased COVID-19 risk in headache patients.
Why the study?
Concerns arose regarding a putative link between the use of drugs such as RAS inhibitors and ibuprofen and an increased risk for COVID-19 infection.
Does the use of RAS inhibitors or ibuprofen increase the risk of COVID-19 infection in headache patients?
Does the use of RAS inhibitors or ibuprofen increase the risk of COVID-19 infection in headache patients?
Current evidence does not support discontinuing RAS inhibitors or ibuprofen in headache patients due to concerns about increased COVID-19 risk.
Reassures against unwarranted discontinuation of RAS inhibitors or ibuprofen in headache patients; leaves open need for prospective confirmation.
The world is currently dominated by the Corona Virus Disease 2019 (COVID-19) pandemic. Besides the obvious concerns about limitation of virus spread and providing the best possible care to infected patients, a concomitant concern has now arisen in view of a putative link between the use of certain drugs, such as Renin-Angiotensin System (RAS) inhibitors and ibuprofen, and an increased risk for COVID-19 infection. We here discuss this concern in relation to headache treatment and conclude that, based on current evidence, there is no reason to abandon treatment of headache patients with RAS inhibitors or ibuprofen.
No takes yet. Share an insight, caveat, or question.
MaassenVanDenBrink et al. (2020) conducted an editorial in Headache and COVID-19. RAS inhibitors and ibuprofen was evaluated. Based on current evidence, there is no reason to abandon treatment of headache patients with RAS inhibitors or ibuprofen during the COVID-19 pandemic.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: